BD MAX Gets CE Mark For Coronavirus Detection, Shares Up
Zacks Investment Research | Mar 10, 2020 09:22PM ET
Becton, Dickinson and Company (NYSE:BDX) , also known as BD, along with CerTest Biotec, recently announced the receipt of CE mark for the VIASURE SARS-CoV-2 real time test adapted for the BD MAX System. Thus, the polymerase chain reaction (PCR) test, used for detecting COVID-19, is now available to clinical laboratories.
Following the release, shares of this Zacks Rank #4 (Sell) company increased 2.8% to $237.31 at close.
For investors’ notice, CerTest Biotec is a Spanish developer and manufacturer of in-vitro diagnostic medical devices.
How Does BD Stand to Gain?
The VIASURE kit is available for use on the BD MAX System. It contains all the components necessary for real-time PCR assay in a stabilized format as well as an internal control to monitor PCR inhibition.
Hence, the latest development is expected to ramp up BD MAX sales in Europe, thereby instilling investors’ optimism in the company. In fact, BD has seen more than 20% growth in BD MAX revenues of late.
Notably, the company recently introduced the COR molecular system, which is also expected to be sold in Europe.
That’s not all. A .
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.